Haura EB - Search Results

1

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Villaruz LC, et al. Among authors: haura eb. Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1. Cancer. 2015. PMID: 25273224 Free PMC article.

2

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.

Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Song L, et al. Among authors: haura eb. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620. Cancer Res. 2006. PMID: 16740687

3

A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.

Li J, Viallet J, Haura EB. Li J, et al. Among authors: haura eb. Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34. doi: 10.1007/s00280-007-0499-3. Epub 2007 May 16. Cancer Chemother Pharmacol. 2008. PMID: 17505826

4

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.

Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Edwards A, et al. Among authors: haura eb. Mol Cancer Ther. 2007 Sep;6(9):2515-24. doi: 10.1158/1535-7163.MCT-06-0761. Mol Cancer Ther. 2007. PMID: 17876048

5

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Simon GR, et al. Among authors: haura eb. Cancer. 2008 May 1;112(9):2021-9. doi: 10.1002/cncr.23360. Cancer. 2008. PMID: 18300255 Free article. Clinical Trial.

6

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. Haura EB, et al. Clin Cancer Res. 2010 Apr 15;16(8):2450-7. doi: 10.1158/1078-0432.CCR-09-1920. Epub 2010 Mar 23. Clin Cancer Res. 2010. PMID: 20332327 Clinical Trial.

7

Molecular origins of lung cancer: prospects for personalized prevention and therapy.

Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Haura EB, et al. J Thorac Oncol. 2010 Jun;5(6 Suppl 3):S207-13. doi: 10.1097/JTO.0b013e3181e2f682. J Thorac Oncol. 2010. PMID: 20502275 Free article.

8

A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.

Haura EB, Sommers E, Song L, Chiappori A, Becker A. Haura EB, et al. J Thorac Oncol. 2010 Nov;5(11):1806-14. doi: 10.1097/JTO.0b013e3181f38f70. J Thorac Oncol. 2010. PMID: 20881637 Free PMC article.

9

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Hammerman PS, et al. Among authors: haura eb. Cancer Discov. 2011 Jun;1(1):78-89. doi: 10.1158/2159-8274.CD-11-0005. Cancer Discov. 2011. PMID: 22328973 Free PMC article.

10

The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics.

Yoshida T, Haura EB. Yoshida T, et al. Among authors: haura eb. Cancer Discov. 2011 Sep;1(4):289-90. doi: 10.1158/2159-8290.CD-11-0193. Cancer Discov. 2011. PMID: 22586609

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters